Opinion

Video

Novel Cardiac Myosin Inhibitors Targeting Obstructive Hypertrophic Cardiomyopathy's Root Cause

Anjali Tiku Owens, MD, examines the unmet needs in treating obstructive hypertrophic cardiomyopathy (oHCM) and explores how novel Cardiac Myosin inhibitors (CMIs) address the root cause of the condition.

  1. The treatment of obstructive hypertrophic cardiomyopathy (oHCM) has a high level of unmet needs, can you discuss these with us?
  • How do novel cardiac myosin inhibitors (CMIs) target the underlying cause of oHCM?

2. What has the impact of CMI’s been on the management of oHCM?

  • Complements (first line) standard of care
  • Addresses the root cause of oHCM
  • Narrowing the substantial gap between effective medical therapy and the more definitive invasive treatments like alcohol septal ablation and surgical myectomy.
Related Videos
Safety Profile, Accessibility of Tapinarof Cream for Atopic Dermatitis, with Adelaide Hebert, MD
Impact of Tapinarof Cream Approval for Atopic Dermatitis, with Adelaide Hebert, MD
Sobia Laique, MD | Credit: Cleveland Clinic
Sobia Laique, MD | Credit: Cleveland Clinic
What is the Global Lung Function Initiative and Its Purpose for Lung Function Testing?
Greg A. Sachs, MD I Credit: Regenstrief Institute
3 experts are featured in this series.
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.